Skip NavigationSkip to Content
NCI HeaderNational Cancer InstituteU.S. National Institutes of Healthwww.cancer.gov
CCR - For Our Staff| Home |
Connecting the Cancer Community with Innovative Science, Breakthrough Therapies and Clinical Advances

Our News

Radiating Good Health more

Dramatic Responses in a Rare Type of Sarcoma more

The GIST of One Cancer: Two Distinct Cellular Diseases more

A Bias for Memory more

In Conversation: Postdoctoral Fellow Alyson Freeman, Ph.D. more

CCR connections

Snorri Thorgerisson, M.D., Ph.D., and Patricia Johnson in CCR's DNA Sequencing Core (Photo: R. Baer) RAS Takes Center Stage
Wreaking cellular havoc in approximately one-third of all cancers, oncogenic RAS signaling has been extensively studied in the 30 years since the gene first associated with rat sarcoma virus was identified in human tumors. But, devising anticancer drugs that target RAS proteins has remained frustratingly elusive.
Continue this story

Home | Contact Us | Policies | Accessibility | Viewing Files | Search | CCR - For Our Staff

A service of the National Cancer Institute

National Cancer InstituteNational Institutes of HealthHealth and Human ServicesUSA Gov - Official Web Portal